search
Back to results

Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

Primary Purpose

Gout

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Placebo
Febuxostat
Febuxostat
Febuxostat
Sponsored by
Takeda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Gout focused on measuring Uric Acid, xanthine oxidase, tophi, Drug Therapy

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Hyperuricemia (serum uric acid ≥8.0 mg/dL). Must meet American College of Rheumatology criteria for gout. Must have adequate renal function (serum creatinine <1.5 mg/dL). Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. Exclusion Criteria: History of xanthinuria Alcohol consumption >14/week Has a history of significant concomitant illness. Has active liver disease. Has a body mass index greater than 50 kilogram per meter² (kg/m²) Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Placebo Comparator

    Experimental

    Experimental

    Experimental

    Arm Label

    Placebo QD

    Febuxostat 40 mg QD

    Febuxostat 80 mg QD

    Febuxostat 120 mg QD

    Arm Description

    Outcomes

    Primary Outcome Measures

    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.
    Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 28 visit was summarized.

    Secondary Outcome Measures

    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.
    Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 7 visit was summarized.
    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.
    Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 14 visit was summarized.
    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.
    Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 21 visit was summarized.
    Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.
    Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.
    Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.
    Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.
    Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit
    Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.
    Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.
    Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.
    Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.
    Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.
    Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.
    24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.

    Full Information

    First Posted
    September 9, 2005
    Last Updated
    July 27, 2011
    Sponsor
    Takeda
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00174967
    Brief Title
    Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
    Official Title
    Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2001 (undefined)
    Primary Completion Date
    July 2001 (Actual)
    Study Completion Date
    July 2001 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Takeda

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout.
    Detailed Description
    Gout is a chronic urate crystal deposition disorder, which if left untreated may result in progressive disease characterized by joint and bone destruction from tophaceous deposits and renal impairment due to gouty nephropathy. Hyperuricemia, defined as a serum urate concentration of >7.0 milligrams per deciliter (mg/dL), is the underlying metabolic aberration leading to urate crystal deposition in gout. Gout has several clinical presentations, including: recurrent acute attacks of inflammatory arthritis; deposition of monosodium urate monohydrate crystals in joints, bones and even parenchymal organs (tophaceous gout); renal impairment; and uric acid nephrolithiasis. As serum urate levels increase beyond >7.0 mg/dL, the risks for gouty arthritis or for renal calculi increase. Currently allopurinol is the only xanthine oxidase inhibitor available. Allopurinol is the agent of choice for reduction of serum urate levels in patients with: uric acid overproduction; unresponsive or intolerant to uricosuric agents; impaired renal function; uric acid urolithiasis; or tophi. Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gout
    Keywords
    Uric Acid, xanthine oxidase, tophi, Drug Therapy

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    153 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo QD
    Arm Type
    Placebo Comparator
    Arm Title
    Febuxostat 40 mg QD
    Arm Type
    Experimental
    Arm Title
    Febuxostat 80 mg QD
    Arm Type
    Experimental
    Arm Title
    Febuxostat 120 mg QD
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Febuxostat
    Other Intervention Name(s)
    TMX-67, Tei-6720, Uloric
    Intervention Description
    Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Febuxostat
    Other Intervention Name(s)
    TMX-67, Tei-6720, Uloric
    Intervention Description
    Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Febuxostat
    Other Intervention Name(s)
    TMX-67, Tei-6720, Uloric
    Intervention Description
    Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
    Primary Outcome Measure Information:
    Title
    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.
    Description
    Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 28 visit was summarized.
    Time Frame
    Day 28.
    Secondary Outcome Measure Information:
    Title
    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.
    Description
    Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 7 visit was summarized.
    Time Frame
    Day 7.
    Title
    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.
    Description
    Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 14 visit was summarized.
    Time Frame
    Day 14.
    Title
    Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.
    Description
    Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 21 visit was summarized.
    Time Frame
    Day 21.
    Title
    Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.
    Description
    Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.
    Time Frame
    Baseline and Day 7.
    Title
    Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.
    Description
    Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.
    Time Frame
    Baseline and Day 14.
    Title
    Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit
    Description
    Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.
    Time Frame
    Baseline and Day 21.
    Title
    Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.
    Description
    Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.
    Time Frame
    Baseline and Day 28.
    Title
    Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.
    Description
    Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.
    Time Frame
    Baseline and Any visit (Day 7, 14, 21,or 28)
    Title
    Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.
    Description
    24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.
    Time Frame
    Baseline and Day 28.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Hyperuricemia (serum uric acid ≥8.0 mg/dL). Must meet American College of Rheumatology criteria for gout. Must have adequate renal function (serum creatinine <1.5 mg/dL). Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. Exclusion Criteria: History of xanthinuria Alcohol consumption >14/week Has a history of significant concomitant illness. Has active liver disease. Has a body mass index greater than 50 kilogram per meter² (kg/m²) Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Director
    Organizational Affiliation
    Takeda
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    15751090
    Citation
    Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar;52(3):916-23. doi: 10.1002/art.20935.
    Results Reference
    result
    PubMed Identifier
    16911575
    Citation
    Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006 Oct;60(10):1210-7. doi: 10.1111/j.1742-1241.2006.01104.x. Epub 2006 Aug 15.
    Results Reference
    result
    PubMed Identifier
    21572152
    Citation
    Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol. 2011 Jul;38(7):1385-9. doi: 10.3899/jrheum.101156. Epub 2011 May 15.
    Results Reference
    result
    Links:
    URL
    http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&fileTypeCode=ULORICPI
    Description
    Uloric Package Insert

    Learn more about this trial

    Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

    We'll reach out to this number within 24 hrs